First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC-Reference-Cited by-同舟云学术

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC

Published:2024-07-10 Issue:9 Volume:24 Page:893-904
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Peterlin Pierre¹,Saada-Bouzid Esma²,Moskovitz Mor³⁴,Pigneux Arnaud⁵,Yuda Junichiro⁶,Sinnollareddy Mahipal⁷,Henner William R.⁸,Chen Diana⁸,Freise Kevin J.⁷,Leibman Rachel S.⁸,Avigdor Abraham⁹¹⁰,Shimizu Toshio¹¹¹²

Affiliation:

1. Hematology Department, Nantes University Hospital, Nantes, France

2. Department of Medical Oncology, Cote d’Azur University, Centre Anticancer Antoine Lacassagne, Nice, France

3. Division of Oncology, Thoracic Cancer Service, Haifa, Israel

4. Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel

5. Department of Hematology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

6. Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan

7. AbbVie Inc, North Chicago, IL, USA

8. AbbVie Inc, San Francisco, CA, USA

9. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel

10. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

11. Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

12. Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama Medical University Graduate School of Medicine, Wakayama, Japan

Funder

Abbvie. ABBV-184 was developed

AbbVie. AbbVie funded this study

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2373888

Reference28 articles.

1. Treat cancers by targeting survivin: Just a dream or future reality?

2. Survivin is highly expressed in CD34+38− leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

3. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia

4. Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients

5. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia